Combination pharmacotherapy in lipid management.
10.5124/jkma.2015.58.8.745
- Author:
Sang Hak LEE
1
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac
- Publication Type:Original Article
- Keywords:
Ezetimibe;
Fibric acids;
Niacin;
Fatty acids;
omega-3
- MeSH:
Diabetic Angiopathies;
Drug Therapy*;
Ezetimibe;
Fatty Acids;
Fibric Acids;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Niacin
- From:Journal of the Korean Medical Association
2015;58(8):745-749
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Latest guidelines on lipid management recommend statins as the first-line therapy. Because limited evidence is available on cardiovascular outcomes with varying statin-nonstatin combinations, recommendation levels for these regimens have been weak. However, a recent trial has demonstrated the additive effect of the statin-ezetimibe combination. The statin-fibrate combination has shown an effect in certain subgroups and on diabetic microangiopathy. Recent trials using the statin-niacin combination have been largely negative, whereas the statin-omega-3 fatty acids combination demonstrated a positive effect only in one study. Identifying the benefits and limitations of each combination is important for the best possible management of patients.
